je.st
news
Tag: cancer
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Non-Small Cell Lung Cancer, and Grants Priority Review
2015-06-01 22:34:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYNOTE-001 Data Served as the Basis for U.S. FDA Filing and Breakthrough Therapy Designation in Advanced NSCLC Across Histologies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on or after platinum-containing chemotherapy and an FDA-approved therapy for EGFR or ALK genomic tumor aberrations, if present. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
ASCO Report Card: Grading Biotech and Cancer Drug Stocks
2015-06-01 16:19:45| Logistics - Topix.net
I spent a long weekend in chilly, rainy Chicago listening to endless cancer-drug data presentations at the American Society of Clinical Oncology annual meeting. Here are my flash impressions on the biotech and drug companies at this huge cancer conference, and whether they come out looking stronger or weaker.
Oncothyreon Breast Cancer Drug Exits ASCO '15 With Good Buzz
2015-06-01 14:09:24| Biotech - Topix.net
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 9+ You may proceed to the site by clicking here , however some pages might not work correctly.
Bristol's Melanoma Drug Combo Is A Cancer Breakthrough. Who Will Get It And Who Won't?
2015-05-31 15:28:09| Biotech - Topix.net
A new cancer treatment from Bristol-Myers Squibb saved Gary McLaughlin's life, but it also landed him in the hospital. Mclaughlin, 75, developed melanoma, the deadly skin cancer, just as he was retiring for real.
Biden announces death of son, Beau, of brain cancer
2015-05-31 06:13:22| Telecom - Topix.net
A recycling center in the Silicon Valley is looking for a woman who dropped off an old Apple computer that turned out to be a collectible item worth $200,000. A handful of volunteers trudged along the muddy and brush-filled banks of the Blanco River in Central Texas, searching for a group of people still missing days after the vacation house where they were staying was... The seemingly ceaseless rain swept across areas of soggy Texas again on Saturday although new serious flooding appeared to be avoided.
Sites : [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] next »